LOG IN
SIGN UP
MARKET
FBIO
FBIO
Fortress Biotech Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.9004
+0.0550
+6.51%
After Hours: 0.8800 -0.0204 -2.27% 17:23 05/27 EDT
OPEN
0.8600
PREV CLOSE
0.8454
HIGH
0.9200
LOW
0.8250
VOLUME
372.96K
TURNOVER
0
52 WEEK HIGH
4.490
52 WEEK LOW
0.7900
MARKET CAP
96.71M
P/E (TTM)
-1.0486
1D
5D
1M
3M
1Y
5Y
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity
SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products ...
GlobeNewswire · 4d ago
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference
SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment...
GlobeNewswire · 5d ago
BRIEF-Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
reuters.com · 05/19 13:43
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will pre...
GlobeNewswire · 05/19 12:30
Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences
MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product ca...
GlobeNewswire · 05/18 12:30
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global ...
ACCESSWIRE · 05/16 17:20
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency
Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in EuropeWALTHAM, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-sta...
GlobeNewswire · 05/13 12:30
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 35.71% and 19.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 21:35
No Data
Learn about the latest financial forecast of FBIO. Analyze the recent business situations of Fortress Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 6 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FBIO stock price target is 9.42 with a high estimate of 24.00 and a low estimate of 3.500.
Current 0.9004
EPS
Actual
Estimate
-0.26-0.14-0.020.10
Institutional Holdings
Institutions: 109
Institutional Holdings: 33.52M
% Owned: 31.20%
Shares Outstanding: 107.41M
TypeInstitutionsShares
Increased
28
1.93M
New
15
1.16M
Decreased
23
562.57K
Sold Out
11
450.24K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Lindsay Rosenwald
Vice Chairman/Executive Director
Michael Weiss
Vice Chairman/Director
Eric Rowinsky
Chief Financial Officer/Treasurer/Secretary
Robyn Hunter
Senior Vice President
George Avgerinos
Independent Director
Jimmie Harvey
Independent Director
Malcolm Hoenlein
Independent Director
Dov Klein
Independent Director
J. Jay Lobell
Independent Director
Kevin Lorenz
No Data
No Data
About FBIO
Fortress Biotech, Inc. (Fortress) is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. Fortress has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, and at its partner companies. Its product candidates span six market areas, including oncology, rare diseases and gene therapy. The Company's commercialized products include Ximino, Targadox, Exelderm, Ceracade, Luxamend and Accutane. Its late-stage product candidates include Intravenous (IV) Tramadol, CUTX-101, MB-107 and MB-207, Cosibelimab, CK-101, CAEL-101, Triplex and CEVA101. Its product candidates also consist of MB-102 (CD123 CAR T for BPDCN), MB-101 (IL13Ra2 CAR T for Glioblastoma), MB-104, MB-106, MB-103, AVTS-001, CK-103 and ConVax. The Company operates in two operating and reportable segments: Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
Webull offers kinds of Fortress Biotech Inc stock information, including NASDAQ:FBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBIO stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading FBIO stock methods without spending real money on the virtual paper trading platform.